Macugen Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of age-related macular degeneration, increasing diagnosis of diabetic eye disorders, expansion of ophthalmology specialty clinics, early adoption of anti-vegf therapies, improved retinal imaging capabilities.

The growth in the forecast period can be attributed to increasing demand for extended-release ocular formulations, growing investments in retinal disease research, rising adoption of personalized ophthalmic treatments, expansion of aging population eye care services, increasing focus on reducing injection frequency. Major trends in the forecast period include increasing use of targeted anti-vegf therapies, rising adoption of intravitreal injection treatments, growing focus on vision preservation therapies, expansion of retinal disease management protocols, enhanced emphasis on long-term treatment efficacy.

The increasing prevalence of age-related macular degeneration (AMD) is anticipated to drive the growth of the macugen market in the coming years. Age-related macular degeneration (AMD) is a progressive ocular disorder that impacts the macula, the central region of the retina responsible for sharp and detailed vision. The growing prevalence of age-related macular degeneration (AMD) is linked to a rapidly aging global population, longer life expectancy, and lifestyle-related factors such as smoking, unhealthy dietary habits, and extended exposure to ultraviolet (UV) radiation. Macugen is used in the treatment of age-related macular degeneration (AMD) as it inhibits vascular endothelial growth factor (VEGF), limits abnormal blood vessel formation and fluid leakage in the retina, and helps maintain vision while slowing disease progression. For instance, in May 2023, according to an article published by the National Center for Biotechnology Information, a US-based government agency under the National Institutes of Health, nearly 288 million people worldwide are projected to be affected by age-related macular degeneration (AMD) by 2040. Consequently, the rising prevalence of age-related macular degeneration (AMD) is fueling the growth of the macugen market.

The increasing emphasis on eye care is expected to drive the growth of the macugen market in the coming years. Eye care encompasses the practices and medical treatments aimed at preserving or enhancing vision and maintaining overall eye health. The heightened focus on eye care is driven by the rising incidence of eye-related disorders, an aging population, and growing awareness about the importance of maintaining good vision. Macugen plays a key role in eye care by treating age-related macular degeneration (AMD) through the inhibition of abnormal blood vessel growth in the retina, thereby helping to prevent vision loss and improve visual clarity. For instance, in November 2023, according to an article published by Nature, a UK-based journal, and in August 2024, according to the Welsh Government, a United Kingdom-based government organization, the number of sight tests paid for by the NHS in Wales during 2023-24 reached a record high of just over 841,000, marking a 6.6% increase compared to 2022-23. Therefore, the growing focus on eye care is contributing to the expansion of the macugen market.

A major trend shaping the macugen market is the advancement of gene therapy. Gene therapy entails delivering genetic material into a patient’s cells to treat or prevent disease, with a specific focus on addressing age-related macular degeneration (AMD). For example, in 2023, Regenxbio, a U.S.-based biotechnology company, introduced RGX-314, a gene therapy designed to deliver a gene that produces an anti-VEGF protein directly into the eye. This novel approach is intended to offer sustained therapeutic benefits by minimizing the need for frequent injections. Distinctive aspects of RGX-314 include its potential for single-dose administration, which may greatly enhance patient adherence, and its capability to address the root causes of AMD rather than only alleviating symptoms. Collectively, these developments strengthen the competitive positioning of companies within the rapidly evolving field of ocular therapeutics.

Major companies operating in the macugen market are Bausch + Lomb Inc.

North America was the largest region in the macugen market in 2025. The regions covered in the macugen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macugen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the macugen market by increasing costs of imported biologic raw materials, sterile syringes, ophthalmic-grade packaging, and cold-chain logistics components. Hospitals and specialty eye clinics in North America and Europe are most affected due to reliance on imported biologics and formulation inputs, while Asia-Pacific faces higher costs for clinical-grade manufacturing and distribution. These tariffs are raising overall treatment costs and tightening reimbursement margins. However, they are also promoting regional biologics manufacturing, localized packaging operations, and improved supply chain control for ophthalmic injectables.

The macugen market research report is one of a series of new reports that provides macugen market statistics, including macugen industry global market size, regional shares, competitors with a macugen market share, detailed macugen market segments, market trends and opportunities, and any further data you may need to thrive in the macugen industry. This macugen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Macugen (pegaptanib sodium) is an anti-vascular endothelial growth factor (VEGF) drug used to manage retinal disorders by blocking the development of abnormal blood vessels in the eye. Its role is to help limit vision loss and prevent additional damage resulting from these irregular blood vessels. The standard recommended dose of Macugen is 0.3 mg, given once every six weeks by an ophthalmologist under sterile conditions.

The primary indication types of Macugen include wet AMD (age-related macular degeneration) and diabetic macular edema. Wet age-related macular degeneration (wet AMD) is a progressive ocular disorder characterized by the growth of abnormal blood vessels beneath the retina, resulting in loss of central vision. These are offered in various formulations, including intravitreal injections and extended-release options. The product is distributed through hospitals and clinics, as well as retail and specialty pharmacies. In addition, it is used by multiple end users, such as adult patients and geriatric patients.

The macugen market consists of sales of pegaptanib sodium injections and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.